To determine if aerosol granulocyte macrophage-colonystimulating factor (GM-CSF) decreases the 2-year pulmonary metastasis rate for soft tissue sarcoma.
improvements in local control, metastasis remains a problem with approximately 50% of patients developing metastasis with the majority of the metastasis occurring in the lung. In our previous study, up to 15% developed pulmonary metastasis within 2 years despite aggressive chemotherapy. 7 Novel approaches are needed to decrease pulmonary metastasis (P-METS).
Granulocyte macrophage-colony-stimulating factor (GM-CSF), well known as a hematopoietic agent, has been shown to stimulate antitumor effects through continued local exposure in cancer cells. Long-lasting antitumor immunity has already been induced in mice through the use of GM-CSF. A phase I study by Anderson et al 10 showed that aerosolized GM-CSF at a dose of 240 mcg bid for 7 days given on alternate weeks and with a rest week between treatment weeks resulted in no toxicity over the course of several months. Rao et al 11, 12 showed that there is clinical activity for pulmonary metastasis in solid tumors with aerosolized GM-CSF. The rationale for the implementation of GM-CSF in the treatment of soft tissue sarcomas comes from the above evidence and the hope that the hematopoietic properties of GM-CSF will help to offset the immunosuppressive properties of most existing antineoplastic therapies available for treating soft tissue sarcomas and improve the 2-year P-METS rate.
PATIENTS AND METHODS

Patient Selection
Patients with potentially curable histologically confirmed nonmetastatic high-grade soft tissue sarcoma at an extremity or limb girdle were selected for this study. Further inclusion criteria required the patient to be a candidate for preoperative radiation before a limb-sparing surgery, at least 18 years of age, have an ECOG performance status no greater than 2, and having adequate blood parameters (ie, WBCZ3500 mL or Z1500 granulocytes, platelets Z150,000 mL, direct-reacting bilirubin r0.3 mg/dL, and creatinine r1.2 times the institutional upper limit of normal). Patients were excluded from the study if they had a significant infection; active heart disease; symptomatic pulmonary disease; had previous cancer chemotherapy or irradiation; had metastatic disease; had either embryonal rhabdomyosarcoma or extraosseous Ewing sarcoma; or females who were either pregnant, nursing, or of child-bearing potential and unwilling to use adequate contraception. The study was approved by the Institutional Review Board and all patients reviewed and signed the informed consent.
Study Design
This is a prospective phase II study where patients received ifosfamide, mitomycin, doxorubicin, cisplatin (I-MAP) and GM-CSF for two 28-day cycles. I-MAP consists of 2500 mg/m 2 ifosfamide on days 1 and 2, 4 mg/m 2 of mitomycin on day 2, 40 mg/m 2 of doxorubicin on day 2, and 60 mg/m 2 of cisplatin on day 2. Subcutaneous GM-CSF was self-administered by the patient beginning 6 days before chemotherapy and continuing for 4 days on a twice daily dosing schedule of 250 mcg/m 2 . The same dosing schedule was followed for 14 days after chemotherapy. Irradiation began 4 weeks after the second cycle of I-MAP. The total dose of irradiation to be delivered was 4500 to 5000 cGy in Z25 treatment fractions (180 cGy per fraction, once daily for 5 days [Monday to Friday]). In some cases, the initial field received 3960 cGy, followed by a boost to a smaller field of 540 cGy for a total of 4500 cGy. Patients received MAP 2Â on days 1 and 28 with radiation and aerosolized GM-CSF. MAP consisted of 6 mg/m 2 mitomycin, 30 mg/m 2 doxorubicin, and 45 mg/m 2 cisplatin. The day after initiating day 1 of MAP, patients received twice a day dosing of aerosol GM-CSF at 250 mcg for days 1 to 7, 15 to 21, and 29 to 35 as described by Anderson et al. 10 Patients were evaluated 4 weeks after completion of preoperative irradiation and concurrent chemotherapy for curative surgery. Patients were allowed to receive a boost dose of radiation with either perioperative brachytherapy or IOERT (intraoperative electron radiotherapy) or intraoperative highdose rate brachytherapy (IOHDR). The choice of boost technique was at the discretion of the radiation oncologist and depended on the location and geometry of the surgical bed and surrounding normal tissues. Doses were dependent on clinical and pathologic margin status. IOERT doses ranged from 750 to 2000 cGy prescribed at the 90% isodose depth. Patients with margins >2 mm were to receive 750 to 1000 cGy, those with negative but r2 mm received 1000 to 1250 cGy, those with R1 resection received 1250 to 1500 cGy, and those with R2 resection received 1500 to 2000 cGy. IOHDR doses were the same with dose specified 5 mm from the surface of the applicator. Perioperative brachytherapy doses were 1200 to 1600 cGy in 3 to 4 fractions delivered twice daily 3 to 5 days after surgery if performed with high-dose rate brachytherapy and 1000 to 2000 cGy at a dose rate of 50 to 65 cGy an hour for low-dose rate brachytherapy. If brachytherapy boost was not performed, an external beam boost was to be performed 2 to 4 weeks postoperatively, including the tumor bed plus 2 to 4 cm margins with 1400 cGy in 7 fractions. Four weeks postoperative, patients received the same aerosolized GM-CSF at 250 mcg twice a day for 7 days followed by 7 days of rest. This was repeated 4 Â for a total of 5 weeks of postoperative aerosolized GM-CSF. Patients were followed every 3 months for 1 year, every 4 months for 1 year, and every 6 months for 2 years, and then once at 1 year. Imaging studies at each visits included MRI of the treated area and CT of the chest with routine CBC and chemistries.
Disease Assessment
All eligible patients initiating treatment and that had at least one postbaseline disease assessment were evaluable for the primary endpoint of to evaluate the 2-year pulmonary metastatic progression rate. Tumor response was assessed using the RECIST with reevaluation every 4 weeks. 13 Radiologic studies were performed at baseline and after every 2 cycles (ie, every 8 wk) of therapy to assess tumor response.
Survival time was calculated as the time from registration to death due to any cause. Progression-free survival was calculated as the time from registration to death or disease progression, whichever was first. Duration of I-MAP response was calculated from time of first response on I-MAP therapy to the time of progression. Patients who did not progress before surgery were censored at the date the surgery was performed. The disease-free interval after surgery was calculated as the date of curative surgery to the date of progression and for patients having been rendered disease free at surgical debulking. If a patient died without progression then progression at death was assumed unless documentation to the contrary was available. All patients were followed for a maximum of 10 years from registration or death, whichever was earlier.
Statistical Methods
The primary endpoint of this trial was 2-year pulmonary metastatic-free rate (2 y P-METS free). All eligible patients who underwent protocol-specified therapy were assessed for the primary and secondary endpoints. The 2-year P-METS-free rate was calculated as the number of patients free from P-METS after 2 years divided by the total number of evaluable patients. A 3-outcome phase II study design (2001) with a planned interim analysis was used to assess whether the 2-year P-METS-free rate was at least 90% (clinically promising) versus at most 75% (clinically inactive). A total of 35 patients were to be enrolled with a planned interim analysis in the first 13 evaluable patients. Absence of P-METS within 2 years in 11 of the first 13 eligible patients enrolled justified continuing enrollment to a total of 39 patients. The final decision rule was one of 3 outcomes: (1) "ineffective" if at most 27 patients were P-METS free at 2 years; (2) "effective" if 30 patients were P-METS free at 2 years; or (3) "inconclusive" if 28 or 29 patients were P-METS free at 2 years. This study was designed to have 90% power at the 0.05 level of significance to detect a P-METS-free rate of at least 90%. Confidence intervals were calculated using the method of Duffy and Santner. 14 Summary statistics and frequency tables were used to describe baseline characteristics and adverse event information. Hematologic adverse events were collected as a minimum value (ie, nadir) per course of treatment and have been converted to a common grading scale (National Cancer Institute Common Toxicity Criteria for Adverse Events, version 2.0). Attribution for all adverse events was also collected. The Kaplan-Meier 15 method was used to estimate survival, pulmonary metastases-free survival, and progression-free survival. All analysis was conducted using SAS version 8.0 (SAS Institute, Cary, NC). Two sided P-values are reported and P < 0.05 is considered statistically significant.
RESULTS
Patient Characteristics
A total of 39 patients were enrolled between November 2001 and April 2006. One patient was excluded from analysis because the patient did not begin cycle 1 of I-MAP due to refusal of the patient's insurance company to support treatment at a Mayo facility. The median age was 51 years (range, 19 to 65 y). At study entry, the median lesion size was 9 cm (range, 2.3 to 26.5 cm) and about 40% of patients presented with disease of the proximal extremity. Further patient characteristics are summarized in Table 1 . Ninety-two percent of patients completed I-MAP and subcutaneous GM-CSF. Eighty-nine percent of patients completed MAP with GM-CSF and radiation, with a median external beam radiation dose of 5000 cGy (range, 4500 to 5400 cGy). Seventy-nine percent of patients underwent limb-salvage surgery and all but one was rendered disease free at that time. Twenty of 28 patients (71%) completed all the postoperative aerosolized GM-CSF.
Treatment Outcome
Twenty-four of the initial 35 evaluable patients were free of P-METS at 2 years (69%, 95% CI, 41%-84%), which failed to meet the prespecified criteria for efficacy. Overall, 73% (95% CI, 60%-89%) of patients (28 of 38) were free of P-METS at 2 years. Eighty-two percent (95% CI, 70%-95%) of patients were still alive after 3 years, with a median follow-up of 5.5 years (range, 3.4 to 7.6 y). Fifty-eight percent (95% CI, 44%-76%) of patients remained progression free after 3 years ( Table 2 and Fig. 1 ) Sixty-nine percent (95% CI, 54%-88%) of patients were disease free 3 years. The percent change in maximum tumor diameter at the end of neoadjuvant chemotherapy and at the end of chemoradiation therapy are shown in Figure 2 . Most of the patients had stable disease (ie, within ± 20% change from baseline) during IMP, with 8 of 33 showing at least a 20% reduction in tumor size. During MAP + XRT, 18 of 30 patients continued to experience further reductions by at least 10%. For those 20 out of 28 patients that completed all 10 cycles of aerosol GM-CSF, the 2-year pulmonary metastasis-free rate is 90% (95% CI, 78%-100%).
Toxicity
All 38 patients were eligible for adverse event evaluation. The most prevalent grade 4 adverse events, regardless of attribution to therapy, were neutropenia (n = 30), leukopenia (n = 12), and thrombocytopenia (n = 6). Severe adverse events experienced by patient and considered at least possibly related to study treatment are shown in Table 3 . Hematologic toxicity was at expected levels for this treatment strategy. Table 4 displays toxicity by treatment phase.
DISCUSSION
Patients with large, high-grade STS are at risk of metastatic disease. Efforts to improve outcomes in this group of patients with the use of adjuvant chemotherapy have shown promising results, but the clinical benefits are still debated today. [16] [17] [18] [19] [20] [21] Our study evaluated the novel approach of adding aerosolized GM-CSF to an aggressive chemotherapy regimen with the hope that we could decrease the 2-year P-METS rate. Although the aerosolized GM-CSF was well tolerated, the overall 2-year P-METS-free rate observed for our trial was 73% (28/35). We did not reach our prespecified statistical benchmark of at least 75% P-METS free at 2 years. Despite not reaching the prespecified benchmark, our approach compares favorably with other studies using neoadjuvant chemotherapy. The RTOG using preoperative MAID (mesna, doxorubicin, ifosfamide, dacarbazine) with radiation had a 3-year distant disease-free survival of 64% and Schuetze and colleagues using combination chemotherapy before surgery had a 61% metastasis-free rate. 22, 23 It is noted, however, our previous study using neoadjuvant chemotherapy and radiation therapy without aerosolized GM-CSF had an estimated 2-year P-MET-free rate of 85%. 7 So at this time, we cannot justify the use of aerosolized GM-CSF as an adjuvant to decrease P-MET rate and newer approaches to control micrometastatic disease are needed. Given the small study size, one reason this study failed to reach the primary endpoint could be that only 71% of the patients continued the maintenance GM-CSF through 10 cycles. The main reason for discontinuation was patient compliance.
The neoadjuvant approach to large, high-grade tumors does provide clinical information about the response to chemotherapy and concurrent chemotherapy with radiation. In our study, only 1 patient (3%, Fig. 2 ) had RECIST progression after 2 cycles of neoadjuvant chemotherapy and 27% (9 of 33, Fig. 2 ) had MRI evidence of growth of the tumor <20%. Even after concurrent chemotherapy and radiation therapy only 9% (3 of 33) of patients had a partial response per RECIST. Using tumor shrinkage to predict outcome has been difficult and some have advocated using PET. 23 But despite the low RECIST response rate and some evidence that these tumors actually enlarge in size (largely from necrosis) during neoadjuvant therapy, the overall survival at 3 years of 82% is encouraging. Our study results with large high-grade sarcomas compares favorably with other studies. Long-term follow-up from the RTOG 9514 recently reported the 5-year survival rate to be 71.2% 22 and from our previous study, the estimated 5-year survival was 80%. 7 Overall the neoadjuvant approach with chemotherapy and radiation therapy for large high-grade sarcoma is feasible and the addition of inhalation GM-CSF failed to reach our study endpoint to improve 2-year metastasis rate. Further study of novel agents on an adjuvant or neoadjuvant basis is needed.
